Mutation in gyrA gene
Number of samples (n) Conclusion. This study showed a higher proportion of M. tuberculosis susceptibility at 2 µg/dL rather than at 0.5 µg/dL, to moxifloxacin for gyrA mutations Ala90Val (MUT1), Asp94Ala (MUT3A), Asp94Gly (MUT3C), Asp94His (MUT3D) but not for Ser91Pro (MUT2) and Asp94Asn/Tyr (MUT3B). However, the number of samples with Ser91Pro (MUT2) and Asp94Asn/Tyr (MUT3B) mutations was too small for meaningful conclusion. This susceptibility at a higher critical concentration of moxifloxacin may have clinical implications for use of high dose moxifloxacin. Since this information is available within a short time frame as provided by LPA, a more effective regimen could be devised 4 to 8 weeks earlier than after results of DST. This may result in faster sputum conversion and prevent amplification of resistance.
Disclosures. . The sensitivity of the combined LF-LAM or sputum microscopy was higher than that of either test alone (86.1% vs. 75.0%, 61.1%, respectively). Mycobacterium avium complex (MAC) was cultured in 7 out of 20 with false positive result. Urine LAM strip test can remain positive for up to 4 weeks even after anti-TB treatment.
Conclusion. Urine LAM assay gave the best performance for diagnosis of active TB in advanced HIV-infected patients and provide an additional benefit of a greater simplicity, speed, with a more easily obtainable sample.
Disclosures. All authors: No reported disclosures. Background. Prompt and accurate identification and differentiation of Mycobacterium tuberculosis-complex (MTBC) from non-tuberculous mycobacteria (NTM) is crucial for the selection of antimicrobial treatment and appropriate public health response. Diagnosis and characterization of mycobacteria is challenging due to diverse clinical presentations, lack of sensitivity of smear microscopy, and fastidious culture identification. Moreover, because of clinical suspicion of noninfectious conditions, specimens are often not processed for culture and formalin-fixed, paraffin-embedded (FFPE) tissues are the only specimens available. For rapid and accurate identification of Mycobacterium spp. from patient tissues, sensitive and specific molecular assays combined with other tissue-based methods are vital.
Improved Detection and Accuracy of Mycobacterium
Methods. We extracted DNA from FFPE tissues from 931 patients with clinical and histopathological suspicion of mycobacterial infection (received during 2013-2016) and evaluated by multistage, multigene targeted Mycobacterium-genus, complexes-and species-specific PCR assays (targets including 16S rRNA, rpoB, groEL, IS6110, RLEP) and sequencing. Tissues were also examined by acid-fast bacilli (AFB) stains and mycobacteria immunohistochemistry (IHC). Assays to detect mutations associated with drug resistance were performed on MTBC cases.
Results. A Mycobacterium species was detected in 465 (50%) cases by PCR and sequencing. Of these, 380 (82%) were positive by Mycobacterium PCR targeting 16S rRNA. 85 cases (18%), including 9 MTBC, 12 M. avium complex and 3 M. leprae, were positive by other PCRs. Co-infection of MTBC and NTM spp. was detected in 5 cases. Of 465 PCR positive cases, 327 (70%) showed immunostaining and 223 (48%) were AFB-positive. Molecular markers for drug resistance were detected in 9 out of 88 (10%) tested MTBC cases.
Conclusion. FFPE tissue analysis by multigene targeted PCR assays expands the opportunities for rapid identification of Mycobacterium species, allows differentiation of MTBC from NTM, and helps to detect co-infections. Using multigene targeted PCRs in combination with histopathology and IHC improve the accuracy of diagnosis, particularly in the presence of commensal and environmental pathogens.
Disclosures. All authors: No reported disclosures. Background. Interferon Gamma Release Assays (IGRAs) and Tuberculin Skin Tests (TSTs) are important adjunctive pediatric TB diagnostics. This study analyzes the use and performance of IGRAs in children diagnosed with active TB disease in a high-resource, low-incidence setting.
Interferon-γ Release Assay Performance in Pediatric Tuberculosis
Methods. We retrospectively reviewed cases of children reported with TB to the California Department of Public Health (CDPH) Tuberculosis Registry during 2010-2015. Our cohort included 778 children, after excluding 68 without an IGRA or TST reported. We analyzed case characteristics associated with test selection and performance, and measured IGRA test sensitivity in children with laboratory confirmed TB disease.
Results. Of the 778 cases of pediatric TB reported, 360 were laboratory confirmed. Children tested with IGRAs were more likely foreign-born, aged ≥5 years, to have extrapulmonary disease only, and be laboratory confirmed, than those tested with TST. Children aged <2 years with confirmed disease were less likely to have a positive IGRA [PRR 0.72 (95% CI 0.55, 0 .93] than children ≥2 years. Indeterminate IGRAs were associated with age <1 year [PRR 9.23, 95% CI 2.87, 29.8) and central nervous system (CNS) disease (PRR 2.69, 95% CI 1.06, 6.86) on multivariate analysis suggesting an association with severe disease. IGRA and TST sensitivity were similar in children <5 years with confirmed disease and test concordance was high in this age group, but sensitivity was <87% for both tests among children aged <2 years. IGRA was more sensitive than TST among children aged 5-18 years (96%, 95% CI 88%-99% vs. 83%, 95% CI 72-91%, P = 0.012).
Conclusion. Children presenting with TB symptoms and disseminated disease were more likely to be tested by IGRA than TST. In children <5 years, IGRA sensitivity is similar to TST, but sensitivity of both tests are reduced in children <2 years. Indeterminate results are higher, particularly in <1 year-olds and in CNS disease. In children aged ≥5 years with laboratory confirmed TB, IGRA has greater sensitivity than TST, and should be considered the preferred immunodiagnostic test. Our data suggest that IGRA is underutilized in this population. Saturday, October 7, 2017: 12:30 PM Background. Rapid and accurate diagnosis of tuberculosis (TB) is important for appropriate treatment initiation and control of disease transmission. Xpert TB/RIF has been widely used for rapid diagnosis especially in sputum AFB smear-negative pulmonary TB. However, about one-third of patients with pauci-bacillary pulmonary TB still reveal negative Xpert TB/RIF results from sputum specimens. Theoretically, bronchoalveolar lavage (BAL) fluid can provide more sensitive specimen in those with sputum-scarce or AFB smear-negative pulmonary TB than sputum.However, there is limited data on the diagnostic performance of Xpert TB/RIF from BAL fluid in patients with pauci-bacillary pulmonary TB.
Methods. All patients with suspected pulmonary TB who underwent BAL due to sputum-scarcity or negative AFB smear results and underwent Xpert TB/RIF from BAL fluid were retrospectively reviewed at a tertiary hospital, Seoul, South Korea (an intermediate TB-burden country) between October 2014 and April 2017. Confirmed TB was defined to those with clinical specimens positive for M. tuberculosis by culture or PCR assays. Patients those with caseating granuloma in biopsy tissue and shows a good response to anti-tuberculous therapy were classified as having probable TB.
Results. A total of 113 patients were included in the analysis. Of these 113 patients, 30 (27%) were classified as confirmed TB, 7 (6%) as probable TB, and 76 (67%) as not TB. Of these 37 patients with confirmed or probable TB, 8 (22%) had miliary TB and 12 (32%) were immunocompromised. Only 15 (50%) of the 30 confirmed TB patients revealed positive Xpert TB/RIF results from BAL fluid. Overall sensitivity, specificity, positive predictive value, and negative predictive value of Xpert TB/ RIF from BAL fluid for the diagnosis of TB were 41% (95% CI, 31%-41%), 100% (95% CI, 95%-100%), 100% (95% CI 77%-100%), and 78% (95% CI 74%-77%), respectively Conclusion. XpertTB/RIF from BAL fluid appears to be suboptimal to rule out pulmonary TB. The development of more sensitive and rapid test for pauci-bacillary pulmonary TB is needed.
Disclosures. All authors: No reported disclosures. 
Season Is Associated with Interferon Gamma Measured in QuantiFERON

